New warnings released for colorectal cancer drug

Article

Rare cases of a brain-capillary leak syndrome called reversible posterior leukoencephalopathy syndrome have led to a revision in the Warnings and Adverse Reactions sections of the prescribing information for bevacizumab (Avastin, Genentech).

Rare cases of a brain-capillary leak syndrome called reversible posterior leukoencephalopathy syndrome have led to a revision in the Warnings and Adverse Reactions sections of the prescribing information for bevacizumab (Avastin, Genentech). The effect occurred at a rate of

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.